On August 3, TG Therapeutics fell 5.37% in pre-market trading, trading at $49.5/share, with turnover of $766,700. The decline was triggered by the company's Q2 earnings report, which showed EPS of $0.05 versus analyst consensus estimates of $0.31-$0.33, missing expectations by approximately 85%.

The reported EPS also represents a 70.59% decrease from $0.17 per share in the same quarter last year. Notably, this marks the third consecutive quarter in which the company has significantly missed earnings expectations, intensifying market concerns over its profitability trajectory. However, Q2 revenue of $240.335 million did beat the $229.721 million estimate, suggesting commercial momentum for its core product BRIUMVI remains intact.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on novel treatments for B-cell mediated diseases. Its flagship product BRIUMVI (Ublituximab), an anti-CD20 monoclonal antibody approved in the US, EU, and UK for relapsing forms of multiple sclerosis, continues to be the primary revenue driver.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)